T. Rowe Price Associates
AZN icon

T. Rowe Price Associates’s AstraZeneca AZN Stock Holding History

T. Rowe Price Associates’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.84B Sell
19,489,220
-4,832,694
-20% -$932M 0.44% 35
2025
Q4 		$4.47B Sell
24,321,914
-240,324
-1% -$42.1M 0.48% 28
2025
Q3 		$3.77B Sell
24,562,238
-1,409,244
-5% -$213M 0.4% 36
2025
Q2 		$3.63B Sell
25,971,482
-2,571,959
-9% -$360M 0.41% 35
2025
Q1 		$4.2B Sell
28,543,441
-1,632,546
-5% -$236M 0.52% 31
2024
Q4 		$3.95B Sell
30,175,987
-1,270,304
-4% -$178M 0.46% 35
2024
Q3 		$4.9B Sell
31,446,291
-1,023,540
-3% -$165M 0.56% 30
2024
Q2 		$5.06B Buy
32,469,831
+1,833,844
+6% +$276M 0.61% 24
2024
Q1 		$4.15B Buy
30,635,987
+4,501,225
+17% +$596M 0.51% 31
2023
Q4 		$3.52B Sell
26,134,762
-737,582
-3% -$95.9M 0.47% 39
2023
Q3 		$3.64B Buy
26,872,344
+449,545
+2% +$61.4M 0.53% 33
2023
Q2 		$3.78B Sell
26,422,799
-2,986,186
-10% -$439M 0.53% 31
2023
Q1 		$4.08B Sell
29,408,985
-4,886,839
-14% -$657M 0.61% 30
2022
Q4 		$4.65B Sell
34,295,824
-3,396,684
-9% -$426M 0.75% 22
2022
Q3 		$4.14B Sell
37,692,508
-5,267,390
-12% -$668M 0.68% 27
2022
Q2 		$5.68B Sell
42,959,898
-4,155,037
-9% -$545M 0.72% 19
2022
Q1 		$6.25B Buy
47,114,935
+2,194,559
+5% +$263M 0.63% 21
2021
Q4 		$5.23B Buy
44,920,376
+3,759,115
+9% +$442M 0.47% 33
2021
Q3 		$4.94B Buy
41,161,261
+7,185,059
+21% +$836M 0.47% 36
2021
Q2 		$4.07B Buy
33,976,202
+4,952,637
+17% +$543M 0.38% 43
2021
Q1 		$2.89B Buy
29,023,565
+19,725,219
+212% +$1.98B 0.29% 69
2020
Q4 		$930M Buy
9,298,346
+1,473,281
+19% +$156M 0.1% 224
2020
Q3 		$858M Buy
7,825,065
+1,020,002
+15% +$113M 0.1% 212
2020
Q2 		$720M Buy
6,805,063
+514,307
+8% +$53.1M 0.09% 230
2020
Q1 		$562M Buy
6,290,756
+278,269
+5% +$26.2M 0.09% 238
2019
Q4 		$600M Sell
6,012,487
-107,248
-2% -$10.1M 0.08% 271
2019
Q3 		$546M Sell
6,119,735
-238,238
-4% -$20.7M 0.08% 259
2019
Q2 		$525M Buy
6,357,973
+747,218
+13% +$58.6M 0.07% 272
2019
Q1 		$454M Sell
5,610,755
-1,264,496
-18% -$99.7M 0.07% 284
2018
Q4 		$522M Buy
6,875,251
+282,764
+4% +$22.1M 0.09% 228
2018
Q3 		$522M Sell
6,592,487
-188,050
-3% -$14.2M 0.08% 262
2018
Q2 		$476M Sell
6,780,537
-747,567
-10% -$53.8M 0.07% 263
2018
Q1 		$527M Buy
7,528,104
+217,977
+3% +$15.1M 0.08% 240
2017
Q4 		$507M Buy
7,310,127
+185,219
+3% +$12.5M 0.08% 252
2017
Q3 		$483M Buy
7,124,908
+933,561
+15% +$59M 0.08% 259
2017
Q2 		$422M Buy
6,191,347
+107,812
+2% +$7.04M 0.08% 280
2017
Q1 		$379M Buy
6,083,535
+833,692
+16% +$48.5M 0.07% 288
2016
Q4 		$287M Buy
5,249,843
+4,612,798
+724% +$262M 0.06% 339
2016
Q3 		$41.9M Buy
+637,045
New +$41.6M 0.01% 871
2014
Q2 		– Sell
-1,467,243
Closed -$95.2M – 2531
2014
Q1 		$95.2M Sell
1,467,243
-436,315
-23% -$28.2M 0.02% 646
2013
Q4 		$113M Buy
1,903,558
+151,820
+9% +$8.25M 0.03% 580
2013
Q3 		$91M Buy
1,751,738
+165,065
+10% +$8.29M 0.02% 618
2013
Q2 		$75M Buy
+1,586,673
New +$80.8M 0.02% 656

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates's AZN Position: Q1 2026 in Review

T. Rowe Price Associates reduced its AstraZeneca (AZN) stake by 20% in Q1 2026, selling an estimated $932M and leaving 19,489,220 shares worth $3.84B. The position accounts for 0.44% of the portfolio, ranked #35.

T. Rowe Price Associates first reported a position in AZN in Q2 2013 and has held it in 43 quarters since. The position peaked at $6.25B in Q1 2022. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • T. Rowe Price Associates held 19,489,220 shares of AstraZeneca worth $3.84B as of Q1 2026.
  • T. Rowe Price Associates sold 4,832,694 AstraZeneca shares in Q1 2026, an estimated $932M.
  • AstraZeneca made up 0.44% of T. Rowe Price Associates's portfolio in Q1 2026, its #35 holding.
  • T. Rowe Price Associates first reported a position in AstraZeneca in Q2 2013 and has held it in 43 quarters since.
  • T. Rowe Price Associates's AstraZeneca position peaked at $6.25B in Q1 2022.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.